Trials / Withdrawn
WithdrawnNCT03629015
Safety Study of Stemchymal® in Acute Liver Failure
The Safety Study of Stemchymal® (Allogeneic Adipose-Derived Mesenchymal Stem Cells) Treating on Acute Liver Failure - An Open-Label, Single-Center Phase I Trial
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Steminent Biotherapeutics Inc. · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety of Stemchymal® via intravenous (IV) infusion in acute liver failure (ALF) and acute on chronic liver failure (ACLF) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Stemchymal® | ALF/ ACLF patients will receive Stemchymal® through intravenous infusion |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2020-05-18
- Completion
- 2020-05-18
- First posted
- 2018-08-14
- Last updated
- 2022-10-28
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03629015. Inclusion in this directory is not an endorsement.